SYHA1813 clinical trials
Also written SYHA1813.
How each study uses SYHA1813 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the SYHA1813 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SYHA1813
- 3
Studies by the year they started
4 studies that test it; most in 2023 (1)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Who runs them
Industry 4 · Other 0
Shanghai Runshi Pharmaceutical Technology Co., Ltd (4)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test SYHA1813.
- Nov 2026Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.Phase 1/2 · Shanghai Runshi Pharmaceutical Technology Co., Ltd
- Jan 2027A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade MeningiomaPhase 2 · Shanghai Runshi Pharmaceutical Technology Co., Ltd
Studies
Open first, then newest update. How each study uses SYHA1813 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Phase III Study of SYHA1813 for Recurrent or Progressive High-Grade MeningiomasNot yet recruitingPhase 3Shanghai Runshi Pharmaceutical Technology Co., LtdNCT07613450Written as SYHA1813
- A Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade MeningiomaNot yet recruitingPhase 2Shanghai Runshi Pharmaceutical Technology Co., LtdNCT06739213Written as SYHA1813
- Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.Not yet recruitingPhase 1/2Shanghai Runshi Pharmaceutical Technology Co., LtdNCT06682611Written as SYHA1813
- Relative Bioavailability and Food Effect of SYHA1813 Oral Solution in Healthy ParticipantsCompletedPhase 1Shanghai Runshi Pharmaceutical Technology Co., LtdNCT06157918Written as SYHA1813 oral solution (2.0g:25mg)